Trial shows high response rates for Merck’s Keytruda
7 June 2016

An analysis of data from a Phase II study of Merck & Co's immunotherapy Keytruda has demonstrated high response rates in heavily pre-treated patients with relapsed or refractory classical Hodgk

Soliris / Myasthenia Gravis Trial Fails to Meet Primary Endpoint
7 June 2016

Results of a phase III trial announced Monday showed that Soliris (Eculizumab) failed to meet its primary study endpoint in patients with refractory generalized myasthenia gravis (gMG).

ASCO: Liquid Biopsy vs Traditional Biopsy
6 June 2016

In a study of over 15,000 patients, researchers have demonstrated the utility of analyzing tumor DNA circulating in blood for advanced solid cancers.

Merck links with Array, Pierre Fabre to test cancer combo
6 June 2016

Germany's Merck has linked with Array BioPharma and Pierre Fabre to initiate a lage-stage trial assessing the efficacy of a new combination therapy in BRAF-mutant metastatic colorectal cancer (CRC)

J&J’s Darzalex improves outcomes in multiple myeloma trial
6 June 2016

Drug Shows Promise for Fragile X Syndrome
6 June 2016

A new treatment for Fragile X syndrome is showing promise.

ASCO: Adding Gene Therapy Doubles Overall Survival of Glioblastoma Patients
6 June 2016

Adding an experimental gene therapy to Avastin (bevacizumab) in patient with recurrent glioblastoma multiforme (GBM) double overall survival.  That is the conclusion of a Phase 2 study present

ASCO: Second ASCT Improves Outcomes in Neuroblastoma Children
5 June 2016

The 50/50 chances of a child surviving high-risk neuroblastoma just got better. Historically, less than 50% of children with high-risk neuroblastoma live 5 or more years after diagnosis.